Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Cloud Computing ETF (CLOU) vs Novo Nordisk A/S (NVO) Price & Performance

Global X Cloud Computing ETFTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Global X Cloud Computing ETF vs Novo Nordisk A/S — how do they compare? Global X Cloud Computing ETF trades at $27.68, while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

CLOUNVO
Sector
Sector/ThematicHealth
52-Week High
$28.09$63.98
52-Week Low
$17.60$35.29
Market Cap
$207.85B
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cloud Computing ETF

CLOU, the Global X Cloud Computing ETF, trades at $27.66, down 1.53% on the day, with a bullish technical signal from moving averages and ADX indicators. The ETF provides diversified exposure to cloud computing stocks, with recent news highlighting long-term growth potential beyond AI hype, driven by strong holdings like Snowflake and Datadog. RSI levels above 80 indicate overbought conditions, suggesting near-term caution.

The outlook for CLOU remains positive due to structural growth in cloud adoption, though high RSI readings and competition from other cloud ETFs pose risks. Investor sentiment is buoyed by resilient subscription revenues and diversification benefits, but volatility in tech stocks and macroeconomic pressures could impact performance.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Cloud Computing ETF

CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.

Read more on CLOU

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO